ALL3
MCID: LKM062
MIFTS: 68

Leukemia, Acute Lymphoblastic (ALL3)

Categories: Blood diseases, Cancer diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Leukemia, Acute Lymphoblastic

MalaCards integrated aliases for Leukemia, Acute Lymphoblastic:

Name: Leukemia, Acute Lymphoblastic 58 76 13 39
Acute Lymphoblastic Leukemia 39 77 54 30 6 17
All 58 54 76
Leukemia, Acute Lymphocytic, Susceptibility to, 1 58 13
Leukemia, Acute Lymphoblastic, Susceptibility to 30 6
B-Cell Acute Lymphoblastic Leukemia 38 17
Acute Lymphocytic Leukemia 54 74
Leukemia, Acute Lymphoblastic, Susceptibility to, 3 74
Precursor Cell Lymphoblastic Leukemia-Lymphoma 45
Precursor Cell Lymphoblastic Leukemia Lymphoma 74
Leukemia Acute Lymphoblastic B-Hyperdiploid 76
Childhood Acute Lymphoblastic Leukemia 76
Leukemia, Acute, Lymphoblastic, T-Cell 41
Leukemia, T-Cell Acute Lymphoblastic 41
Leukemia B-Cell Acute Lymphoblastic 76
Leukemia T-Cell Acute Lymphoblastic 76
Leukemia, Acute Lymphoblastic, 3 76
Leukemia, Lymphocytic, Acute, L1 74
Leukemia Acute Lymphoblastic 1 76
Leukemia, Acute, Lymphoblastic 41
Leukemia, Acute Lymphocytic 1 58
Leukemia Acute Lymphocytic 1 76
Lymphoblastic Leukemia Acute 56
Leukemia Acute Lymphocytic 76
All3 76
All1 76

Characteristics:

HPO:

33
leukemia, acute lymphoblastic:
Inheritance polygenic inheritance


Classifications:



Summaries for Leukemia, Acute Lymphoblastic

NIH Rare Diseases : 54 Acute lymphoblastic leukemia (ALL) is a type of cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell). It may develop in children or adults. ALL spreads to the blood fairly quickly, and then may spread to other areas of the body such as the lymph nodes, liver, spleen, central nervous system, and testicles (in males). Signs and symptoms of ALL may include fever, easy bruising or bleeding, feeling tired, loss of appetite, pain in the bones or abdomen, and painless lumps in the neck, underarm, stomach, or groin. ALL is typically caused by random, non-inherited changes in the DNA of immature lymphocytes called lymphoblasts. However, some people may inherit a genetic susceptibility to developing ALL. The risk to develop ALL may also be increased by past treatment for cancer, and by having certain genetic conditions or syndromes. Having one or more risk factors does not mean that a person definitely will develop ALL. Treatment of ALL depends on the person's age, how advanced the cancer is, and whether certain genetic changes are found in cancer cells. Treatment options may involve systemic and/or intrathecal chemotherapy, radiation therapy, targeted therapy, and/or a stem cell transplant. Biologic therapy and chimeric antigen receptor (CAR) T-cell therapy are currently being studied as treatment options and may be used when other therapies are not working. The chance of recovery also depends on many factors. With treatment, about 98% of children with ALL go into remission, and 85% of those with first-time ALL are expected have no long-term complications. The chance of recovery for adults is not as high, as 20-40% of adults are cured with current treatments.

MalaCards based summary : Leukemia, Acute Lymphoblastic, also known as acute lymphoblastic leukemia, is related to leukemia, acute lymphoblastic 3 and lymphoid leukemia, and has symptoms including angina pectoris, edema and chest pain. An important gene associated with Leukemia, Acute Lymphoblastic is PAX5 (Paired Box 5), and among its related pathways/superpathways are Transcriptional misregulation in cancer and MicroRNAs in cancer. The drugs Methotrexate and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include Blood and Blood, and related phenotypes are acute lymphoblastic leukemia and neoplasm

OMIM : 58 Acute lymphoblastic leukemia (ALL), also known as acute lymphocytic leukemia, is a subtype of acute leukemia, a cancer of the white blood cells. Somatically acquired mutations in several genes have been identified in ALL lymphoblasts, cells in the early stages of differentiation. Germline variation in certain genes may also predispose to susceptibility to ALL (Trevino et al., 2009). (613065)

UniProtKB/Swiss-Prot : 76 Leukemia, acute lymphoblastic: A subtype of acute leukemia, a cancer of the white blood cells. ALL is a malignant disease of bone marrow and the most common malignancy diagnosed in children. The malignant cells are lymphoid precursor cells (lymphoblasts) that are arrested in an early stage of development. The lymphoblasts replace the normal marrow elements, resulting in a marked decrease in the production of normal blood cells. Consequently, anemia, thrombocytopenia, and neutropenia occur to varying degrees. The lymphoblasts also proliferate in organs other than the marrow, particularly the liver, spleen, and lymphnodes. Leukemia, acute lymphoblastic, 3: A subtype of acute leukemia, a cancer of the white blood cells. Acute lymphoblastic anemia is a malignant disease of bone marrow and the most common malignancy diagnosed in children. The malignant cells are lymphoid precursor cells (lymphoblasts) that are arrested in an early stage of development. The lymphoblasts replace the normal marrow elements, resulting in a marked decrease in the production of normal blood cells. Consequently, anemia, thrombocytopenia, and neutropenia occur to varying degrees. The lymphoblasts also proliferate in organs other than the marrow, particularly the liver, spleen, and lymphnodes.

Wikipedia : 77 Acute lymphoblastic leukemia (ALL) is a cancer of the lymphoid line of blood cells characterized by the... more...

Related Diseases for Leukemia, Acute Lymphoblastic

Diseases in the Leukemia, Acute Lymphoblastic family:

Leukemia, Acute Lymphoblastic 2 Leukemia, Acute Lymphoblastic 3

Diseases related to Leukemia, Acute Lymphoblastic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 706)
# Related Disease Score Top Affiliating Genes
1 leukemia, acute lymphoblastic 3 34.4 ETV6 FLT3 PAX5
2 lymphoid leukemia 30.6 ETV6 FLT3 GNB1 NBN
3 bone marrow cancer 30.6 ETV6 FLT3 MIR155
4 dermatomyositis 30.5 MIR130A MIR155 MIR199B
5 glioblastoma 30.4 MIR128-1 MIR130A MIR23A MIR451A
6 polymyositis 30.4 MIR130A MIR155
7 acute leukemia 30.3 ETV6 FLT3 PAX5
8 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 30.3 ETV6 FLT3
9 leukemia, acute myeloid 29.9 ETV6 FLT3 MIR128-1 MIR128-2 MIR130A MIR130B
10 hepatocellular carcinoma 29.9 MIR128-2 MIR130A MIR152 MIR155 MIR199B MIR203A
11 acute lymphoblastic leukemia, childhood 12.9
12 b-cell childhood acute lymphoblastic leukemia 12.8
13 precursor t-cell acute lymphoblastic leukemia 12.5
14 leukemia, acute lymphoblastic 2 12.5
15 acute lymphoblastic leukemia congenital sporadic aniridia 12.3
16 acute t cell leukemia 12.2
17 t-cell childhood acute lymphocytic leukemia 12.1
18 b-cell adult acute lymphocytic leukemia 12.0
19 null-cell leukemia 11.8
20 lymphoblastic lymphoma 11.7
21 acute lymphocytic leukemia 11.7
22 bone marrow necrosis 11.7
23 lymphoblastic leukemia, acute, with lymphomatous features 11.7
24 medulloblastoma 11.7
25 precursor lymphoblastic lymphoma/leukemia 11.6
26 t-cell adult acute lymphocytic leukemia 11.3
27 hematopoietic stem cell transplantation 10.8
28 lymphocytic leukemia 10.7
29 leukemia 10.7
30 prostate cancer 10.6
31 down syndrome 10.6
32 osteonecrosis 10.6
33 carney complex, type 1 10.6
34 caronte 10.6
35 glucocorticoid resistance, generalized 10.6
36 sarcoma 10.5
37 lymphoma, hodgkin, classic 10.5
38 leukemia, chronic myeloid 10.5
39 mucositis 10.5
40 burkitt lymphoma 10.5
41 lymphoma, non-hodgkin, familial 10.5
42 neutropenia 10.5
43 thrombosis 10.5
44 mucormycosis 10.5
45 neuropathy 10.5
46 hypereosinophilic syndrome 10.5
47 pancreatitis 10.5
48 wilms tumor 5 10.5
49 wilms tumor 6 10.5
50 graft-versus-host disease 10.4

Graphical network of the top 20 diseases related to Leukemia, Acute Lymphoblastic:



Diseases related to Leukemia, Acute Lymphoblastic

Symptoms & Phenotypes for Leukemia, Acute Lymphoblastic

Human phenotypes related to Leukemia, Acute Lymphoblastic:

33
# Description HPO Frequency HPO Source Accession
1 acute lymphoblastic leukemia 33 HP:0006721

Clinical features from OMIM:

613065

UMLS symptoms related to Leukemia, Acute Lymphoblastic:


angina pectoris, edema, chest pain

MGI Mouse Phenotypes related to Leukemia, Acute Lymphoblastic:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.1 ACTB ETV6 FLT3 NBN PAX5 PMS2

Drugs & Therapeutics for Leukemia, Acute Lymphoblastic

Drugs for Leukemia, Acute Lymphoblastic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 656)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1959-05-2, 59-05-2 126941
2
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53-03-2 5865
3
Dasatinib Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 302962-49-8 3062316
4
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1177-87-3
5
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-02-2 5743
6
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 143 6006
7
Idarubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58957-92-9 42890
8
Daunorubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 20830-81-3 30323
9
Cytarabine Approved, Experimental, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 147-94-4, 65-46-3 6253
10
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 2068-78-2, 57-22-7 5978
11
Mercaptopurine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-44-2 667490
12
Sargramostim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 123774-72-1, 83869-56-1
13
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 174722-31-7 10201696
14
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
15
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
16
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
17
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
18
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
19
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
20
Pegaspargase Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 130167-69-0
21
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 23214-92-8 31703
22
Cladribine Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 4291-63-8 20279
23
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33419-42-0 36462
24
Thioguanine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 154-42-7 2723601
25
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 75607-67-9, 21679-14-1 30751
26
Vindesine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 53643-48-4, 59917-39-4 40839
27
Teniposide Approved Phase 4,Phase 3,Phase 2,Not Applicable 29767-20-2 34698
28
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 3778-73-2 3690
29
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-03-3
30
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-23-7 5754
31
Mitoxantrone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 65271-80-9 4212
32
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
33
Thiotepa Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 52-24-4 5453
34
Busulfan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 55-98-1 2478
35
Epirubicin Approved Phase 4,Phase 3,Phase 2 56420-45-2 41867
36
Posaconazole Approved, Investigational, Vet_approved Phase 4,Not Applicable 171228-49-2 147912
37
Micafungin Approved, Investigational Phase 4,Phase 2 235114-32-6 477468 3081921
38
Methylphenidate Approved, Investigational Phase 4,Not Applicable 113-45-1 4158
39
Dopamine Approved Phase 4,Not Applicable 62-31-7, 51-61-6 681
40
Oprelvekin Approved, Investigational Phase 4 145941-26-0
41
inotuzumab ozogamicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 635715-01-4
42
Azacitidine Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 320-67-2 9444
43
Decitabine Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 2353-33-5 451668
44
Morphine Approved, Investigational Phase 4,Phase 3,Not Applicable 57-27-2 5288826
45
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 1994-09-7, 94-09-7 2337
46
tannic acid Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 1401-55-4
47
Amphotericin B Approved, Investigational Phase 4,Phase 3,Phase 2 1397-89-3 5280965 14956
48
Nicotine Approved Phase 4 54-11-5 89594 942
49
Tyrosine Approved, Investigational, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1 60-18-4 6057
50
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037

Interventional clinical trials:

(show top 50) (show all 1887)
# Name Status NCT ID Phase Drugs
1 Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor to Treat ph+ Acute Lymphoblastic Leukemia Patients Unknown status NCT02690922 Phase 4 Dasatinib;prednisone;dexamethasone;methotrexate
2 Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia Unknown status NCT01990807 Phase 4 Idarubicin(IDA)
3 The GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia Unknown status NCT00846703 Phase 4 6-mercaptopurine, Methotrexate;6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone
4 German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Unknown status NCT00198978 Phase 4 Cyclophosphamide;Dexamethasone / Prednisolone;Cytarabine;Idarubicin;Granulocyte-Colony-Stimulating Factor;Mercaptopurine;Methotrexate;Rituximab;HDARAC;Vincristine;Depocyte;Asparaginase
5 Medical Research Council (MRC) Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003 Unknown status NCT00222612 Phase 4 Standard childhood UK ALL protocol;Intensified treatment including Capizzi maintenance
6 German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003) Unknown status NCT00198991 Phase 4 Cyclophosphamide;Dexamethasone;Vincristine;daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Prednisolone;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Cladribine
7 Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study Unknown status NCT02894645 Phase 4 Prednisolone;Dexamethasone;L-Asparaginase;Vincristine;Methotrexate;Daunorubicin;Doxorubicin;Cyclophosphamide;Cytarabine;6-Mercaptopurine;Thioguanine;Fludarabine;Imatinib
8 Poly(Ethylene Glycol)(PEG)-Asparaginase During Two Treatment Courses Unknown status NCT00192673 Phase 4 PEG-asparaginase
9 HD-Idarubicin/Etoposide Intensified Conditioning Regimen Allo-HSCT for Adult ALL Unknown status NCT01873807 Phase 4 IDA;CTX;VP-16
10 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
11 Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission Unknown status NCT01901666 Phase 4 Growth Hormone
12 Pulses of Vincristine and Dexamethasone in BFM Protocols for Children With Acute Lymphoblastic Leukemia Completed NCT00411541 Phase 4 vincristine;dexamethasone
13 Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia Completed NCT01358253 Phase 4 Cyclophosphamide;Doxorubicin;Vincristine;Dexamethasone;Cytarabine;Methotrexate;Rituximab;6-Mercaptopurine;Prednisone;L-asparaginase
14 LAL-AR-N-2005:Study Treatment for Children High Risk Acute Lymphoblastic Leukemia Completed NCT00526409 Phase 4 Prednisolone;Daunorubicin;Vincristine;L-Asparaginase;Cyclophosphamide;Methotrexate;Cytosine Arabinoside
15 PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia Completed NCT00494897 Phase 4 Asparaginase;Cyclophosphamide;Cytarabine;Daunorubicin;Mercaptopurine;Prednisone;Vincristine;Methotrexate
16 Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia Completed NCT00199095 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone;Idarubicin;Ifosfamide;Methotrexate;Mercaptopurine;VM26;Vincristine
17 LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive Completed NCT00526305 Phase 4 Vincristine;Daunorubicin;Prednisone;L-Asparaginase;Mitoxantrone;Cytosine Arabinoside;Hydrocortisone;Mercaptopurine;Cyclophosphamide;Dexamethasone
18 ALL-REZ BFM 2002: Multi-Center Study for Children With Relapsed Acute Lymphoblastic Leukemia Completed NCT00114348 Phase 4
19 German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (05/93) Completed NCT00199069 Phase 4 Asparaginase;Vincristine;Daunorubicin, Adriamycin;Cyclophosphamide;Ifosfamide;Cytarabine;Mitoxantrone;Methotrexate;6-Mercaptopurine;6-Thioguanine;VM26;Dexamethasone / Prednisolone
20 German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99) Completed NCT00199056 Phase 4 Dexamethasone / Prednisolone;Cyclophosphamide;Methotrexate;Vincristine / Vindesine;Daunorubicin;Asparaginase;G-CSF;Cytarabine;6-Mercaptopurine;VP16;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Ifosfamide
21 Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab Completed NCT00199004 Phase 4 Cyclophosphamide;Dexamethasone / Prednisolone;Vincristine;Daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Adriamycin;Thioguanine;VM26;Rituximab
22 Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Completed NCT01200355 Phase 4 micafungin;posaconazole
23 Learning Impairments Among Survivors of Childhood Cancer Completed NCT00576472 Phase 4 Methylphenidate
24 LAL-BR/2001: Study Treatment to Low Risk ALL Completed NCT00526175 Phase 4 Prednisone;Vincristine;Daunorubicin;L-Asparaginase;Cyclophosphamide;Methotrexate;Cytosine Arabinoside;Mercaptopurine;VP-16
25 Effect of rhIL-11 in Patients With Thrombocytopenia for Childhood ALL Completed NCT02314273 Phase 4 rhIL-11
26 The Study on the Pharmacokinetics of PEG-rhG-CSF in Children and Adolescents Completed NCT02953730 Phase 4 PEG-rhG-CSF
27 Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-grade Lymphoma in Adults Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
28 German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults Completed NCT00199017 Phase 4 Dexamethasone/Prednisolone;Cyclophosphamide;Vincristine;Daunorubicin;Asparaginase;G-CSF;Mercaptopurine;Cytarabine;Methotrexate;VP16;Vindesine;Adriamycin;Thioguanine;HDARAC;Cladribine
29 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
30 Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase Completed NCT01061177 Phase 4 Nilotinib
31 Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia Recruiting NCT02618109 Phase 4
32 Protocol For the Treatment Acute Lymphoblastic Leukemia With Ph 'Negative in Elderly Patients (> 55 Years) Recruiting NCT01366898 Phase 4 Dexamethasona, Idarubicine, ARA-C, Methotrexate
33 A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients Recruiting NCT03677596 Phase 4 inotuzumab ozogamicin-dose level 2;Inotuzumab ozogamicin-dose level 1
34 Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVE Recruiting NCT01491763 Phase 4 Imatinib
35 Study on Two Different Formulations of 6-mercaptopurine. Tablet Versus Oral Liquid Recruiting NCT01906671 Phase 4 Xaluprine;Puri-Nethol
36 PETHEMA LAL-07FRAIL: All Treatment In Fragile Patients Ph' Negative Over 55 Years Recruiting NCT01358201 Phase 4 vINCRISTINE;Dexamethasone;Methotrexate;Cytosine arabinoside
37 ALL SCTped FORUM - Pharmacogenomic Study (add-on Study) Recruiting NCT02670564 Phase 4
38 Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia Recruiting NCT02036489 Phase 4 Vincristine;Daunorubicin;Prednisone;L-asparaginase;Ciclophosphamide;Metotrexate;ARA-C;Hidrocortisone;Mercaptopurine;VP-16;Dexametasone
39 ATG Based Conditioning Regimen in HLA Related HSCT for Aggressive T-cell Tumors Recruiting NCT02938741 Phase 4 Anti-human Thymoglobulin;Placebo
40 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor Recruiting NCT02933333 Phase 4
41 A Clinical Trial of Decitabine in Relapsed or Refractory T-lymphoblastic Lymphoma Recruiting NCT03558412 Phase 4 Decitabine
42 Treatment of High Risk Adult Acute Lymphoblastic Leukemia Active, not recruiting NCT00853008 Phase 4 Vincristine;Daunorubicin;Prednisone;Mitoxantrone;Cytosine Arabinoside;Dexamethasone;Methotrexate (MTX);Cytarabine;ASP;Mercaptopurine;Teniposide;Hydrocortisone
43 Vaccinating Children After Chemotherapy Active, not recruiting NCT02447718 Phase 4
44 Determinants of Mercaptopurine Toxicity in Paediatric Acute Lymphoblastic Leukemia Maintenance Therapy Enrolling by invitation NCT03920813 Phase 4 Mercaptopurine
45 A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT Enrolling by invitation NCT03176849 Phase 4
46 ProphyALL - Study on the Safety of Liposomal Amphotericin B to Prevent Antifungal Infections in Elderly Patients With Acute Lymphoblastic Leukemia Terminated NCT00386997 Phase 4 liposomal amphotericin B (AmBisome®)
47 Atomoxetine for Children With Acquired Attentional Disorders Following Completion of Chemotherapy for ALL Terminated NCT00299234 Phase 4 Atomoxetine
48 Haplo-identical HSCT Versus Chemotherapy for Adult Acute Lymphoblastic Leukemia Patients Unknown status NCT02042690 Phase 3 Chemotherapy
49 Phase III Study of Vincristine Sulfate Liposome For Injection In Adults With Naïve Acute Lymphoblastic Leukemia Unknown status NCT02072785 Phase 3 Vincristine Sulfate Liposome;Vincristine Sulfate
50 Treatment of Acute Lymphoblastic Leukemia or Aggressive Lymphoma With Relapse in Central Nervous System With Depocyt Unknown status NCT00199108 Phase 2, Phase 3 Depocyt;Dexamethasone

Search NIH Clinical Center for Leukemia, Acute Lymphoblastic

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Leukemia, Acute Lymphoblastic cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: precursor cell lymphoblastic leukemia-lymphoma

Genetic Tests for Leukemia, Acute Lymphoblastic

Genetic tests related to Leukemia, Acute Lymphoblastic:

# Genetic test Affiliating Genes
1 Acute Lymphoblastic Leukemia 30
2 Leukemia, Acute Lymphoblastic, Susceptibility to 30

Anatomical Context for Leukemia, Acute Lymphoblastic

MalaCards organs/tissues related to Leukemia, Acute Lymphoblastic:

42
T Cells, B Cells, Bone, Bone Marrow, Myeloid, Liver, Testes
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Leukemia, Acute Lymphoblastic:
# Tissue Anatomical CompartmentCell Relevance
1 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
2 Blood Peripheral Blood Mature B-Cells Affected by disease
3 Blood Hematopoietic Bone Marrow Small Pre B-Cells Affected by disease

Publications for Leukemia, Acute Lymphoblastic

Articles related to Leukemia, Acute Lymphoblastic:

(show top 50) (show all 7909)
# Title Authors Year
1
Insulin-dependent diabetes: A chronic complication to acute pancreatitis in childhood acute lymphoblastic leukemia. ( 30216644 )
2019
2
Isavuconazole Treatment of Cerebral and Pulmonary Aspergillosis in a Pediatric Patient With Acute Lymphoblastic Leukemia: Case Report and Review of Literature. ( 31094909 )
2019
3
A novel germline SAMD9L mutation in a family with ataxia-pancytopenia syndrome and pediatric acute lymphoblastic leukemia. ( 30923096 )
2019
4
Bladder Artery Embolization for Massive Hematuria Treatment in a Patient With Ataxia-Telangiectasia Acute Lymphoblastic Leukemia. ( 30933018 )
2019
5
Bilateral trifocal IOL implantation in a pediatric case of cataract following steroid-therapy for acute lymphoblastic leukemia. ( 30555958 )
2019
6
Congenital B-cell Acute Lymphoblastic Leukemia with Congenital Rubella Infection. ( 30806367 )
2019
7
Monitoring of cytomegalovirus infection in non-transplant pediatric acute lymphoblastic leukemia patients during chemotherapy. ( 30681620 )
2019
8
Cytomegalovirus Retinitis during Maintenance Therapy in child with Acute Lymphoblastic Leukemia. ( 31086168 )
2019
9
CD20-negative primary middle ear diffuse large B-cell lymphoma coexpressing MYC and BCL-2 secondary to acute lymphoblastic leukemia: A case report. ( 30985716 )
2019
10
Dasatinib and low-intensity chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukemia in a child with Down syndrome. ( 30663211 )
2019
11
Feasibility and Potential Benefits of an Exercise Intervention in a Male With Down Syndrome Undergoing High-Dose Chemotherapy for Acute Lymphoblastic Leukemia: A Case Report. ( 30795696 )
2019
12
Development of acute lymphoblastic leukemia following treatment for acute myeloid leukemia in children with Down syndrome: A case report and retrospective review of Children's Oncology Group acute myeloid leukemia trials. ( 30908863 )
2019
13
Use of inotuzumab-ozogamicin in a child with Down syndrome and refractory B-cell precursor acute lymphoblastic leukemia. ( 30485640 )
2019
14
Posterior reversible encephalopathy syndrome in children with acute lymphoblastic leukemia: Experience of a single center using BFM protocols. ( 30868749 )
2019
15
Invasive fusariosis masquerading as extramedullary disease in rapidly progressive acute lymphoblastic leukemia. ( 30900813 )
2019
16
Growth hormone deficiency and neurocognitive function in adult survivors of childhood acute lymphoblastic leukemia. ( 30690723 )
2019
17
Gene mutations and pretransplant minimal residual disease predict risk of relapse in adult patients after allogeneic hematopoietic stem-cell transplantation for T cell acute lymphoblastic leukemia. ( 30950667 )
2019
18
Strong expression of p53 protein in bone marrow samples after hematopoietic stem cell transplantation indicates risk of relapse in pediatric acute lymphoblastic leukemia patients. ( 30955249 )
2019
19
Blinatumomab for Acute Lymphoblastic Leukemia Relapse After Allogeneic Hematopoietic Stem Cell Transplantation. ( 31002989 )
2019
20
Combination chemotherapy plus dasatinib leads to comparable overall survival and relapse-free survival rates as allogeneic hematopoietic stem cell transplantation in Philadelphia positive acute lymphoblastic leukemia. ( 31016870 )
2019
21
Allogeneic hematopoietic stem cell transplantation from unrelated donors is associated with higher infection rates in children with acute lymphoblastic leukemia - A prospective international multicenter trial on behalf of the BFM-SG and the EBMT-PDWP. ( 31095771 )
2019
22
Hematopoietic Stem Cell Transplantation Does Not Improve the Poor Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group. ( 30742559 )
2019
23
Access to Hematopoietic Stem Cell Transplantation among Pediatric Patients with Acute Lymphoblastic Leukemia: A Population-based Analysis. ( 30769192 )
2019
24
Hematopoietic Stem Cell Transplantation in Pediatric Acute Lymphoblastic Leukemia. ( 30806963 )
2019
25
Higher Reported Lung Dose Received during Total Body Irradiation for Allogeneic Hematopoietic Stem Cell Transplantation in Children with Acute Lymphoblastic Leukemia is Associated with Inferior Survival: A Report from the Children's Oncology Group. ( 30807822 )
2019
26
Chimeric Antigen Receptor-modified Donor Lymphocyte Infusion Improves the Survival of Acute Lymphoblastic Leukemia Patients With Relapsed Diseases After Allogeneic Hematopoietic Stem Cell Transplantation. ( 30829725 )
2019
27
A Single-Center Experience With Hematopoietic Stem Cell Transplantation for Pediatric Acute Lymphoblastic Leukemia: A Modest Pitch for Non-Total Body Irradiation Conditioning Regimens. ( 30295587 )
2019
28
Ikaros family zinc-finger 1 mutation is an independent factor for the poor prognosis of adult B-cell acute lymphoblastic leukemia, and allogeneic hematopoietic stem cell transplantation can improve clinical outcomes. ( 29942002 )
2019
29
Paraneoplastic hypereosinophilic syndrome associated with IL3-IgH positive acute lymphoblastic leukemia. ( 30207070 )
2019
30
Allopurinol reverses mercaptopurine-induced hypoglycemia in patients with acute lymphoblastic leukemia. ( 30828444 )
2019
31
Type B Lactic Acidosis: A Rare Initial Presentation of Childhood Acute Lymphoblastic Leukemia. ( 30814800 )
2019
32
Predisposing germline mutations in high hyperdiploid acute lymphoblastic leukemia in children. ( 31102422 )
2019
33
Long-Term Outcomes of Modified St Jude Children's Research Hospital Total Therapy XIIIB and XV Protocols for Thai Children With Acute Lymphoblastic Leukemia. ( 31103474 )
2019
34
Improving brain function of pediatric acute lymphoblastic leukemia patients after induction chemotherapy, a pilot self-contrast study by fractional amplitude of low-frequency fluctuation. ( 31104963 )
2019
35
Identification and Validation of Novel Reference Genes in Acute Lymphoblastic Leukemia for Droplet Digital PCR. ( 31108950 )
2019
36
CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia. ( 31110217 )
2019
37
ARID5B gene polymorphisms and the risk of childhood acute lymphoblastic leukemia: a meta-analysis. ( 31111395 )
2019
38
Chromosomal microarray analysis is superior in identifying cryptic aberrations in patients with acute lymphoblastic leukemia at diagnosis/relapse as a single assay. ( 31112375 )
2019
39
Severe hyperlipidemia in a case of acute lymphoblastic leukemia. ( 31062741 )
2019
40
The Key Roles of PTEN in T-Cell Acute Lymphoblastic Leukemia Development, Progression, and Therapeutic Response. ( 31064074 )
2019
41
Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia. ( 31073076 )
2019
42
The enhancer RNA ARIEL activates the oncogenic transcriptional program in T-cell acute lymphoblastic leukemia. ( 31076442 )
2019
43
Overlapped differentially expressed genes between acute lymphoblastic leukemia and chronic lymphocytic leukemia revealed potential key genes and pathways involved in leukemia. ( 31081970 )
2019
44
More Is Not Always Better: The Perils of Treatment Intensification in Pediatric Acute Lymphoblastic Leukemia. ( 31084546 )
2019
45
CD9 predicts ETV6-RUNX1 in childhood B-cell precursor acute lymphoblastic leukemia. ( 31085145 )
2019
46
Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2019. ( 31085755 )
2019
47
A Bayesian multivariate latent t-regression model for assessing the association between corticosteroid and cranial radiation exposures and cardiometabolic complications in survivors of childhood acute lymphoblastic leukemia: a PETALE study. ( 31088361 )
2019
48
Identification of genetic association between cardiorespiratory fitness and the trainability genes in childhood acute lymphoblastic leukemia survivors. ( 31088516 )
2019
49
Analysis of apoptotic, platelet-derived, endothelial-derived, and tissue factor-positive microparticles of children with acute lymphoblastic leukemia during induction therapy. ( 31090597 )
2019
50
Recent advances in the treatment of acute lymphoblastic leukemia. ( 31092071 )
2019

Variations for Leukemia, Acute Lymphoblastic

UniProtKB/Swiss-Prot genetic disease variations for Leukemia, Acute Lymphoblastic:

76
# Symbol AA change Variation ID SNP ID
1 PAX5 p.Gly183Ser VAR_070682 rs398123063

ClinVar genetic disease variations for Leukemia, Acute Lymphoblastic:

6 (show top 50) (show all 72)
# Gene Variation Type Significance SNP ID Assembly Location
1 NBN NM_002485.4(NBN): c.511A> G (p.Ile171Val) single nucleotide variant risk factor rs61754966 GRCh37 Chromosome 8, 90990521: 90990521
2 NBN NM_002485.4(NBN): c.511A> G (p.Ile171Val) single nucleotide variant risk factor rs61754966 GRCh38 Chromosome 8, 89978293: 89978293
3 HOXD4 NM_014621.2(HOXD4): c.242A> T (p.Glu81Val) single nucleotide variant Uncertain significance rs104893636 GRCh37 Chromosome 2, 177016603: 177016603
4 HOXD4 NM_014621.2(HOXD4): c.242A> T (p.Glu81Val) single nucleotide variant Uncertain significance rs104893636 GRCh38 Chromosome 2, 176151875: 176151875
5 FLT3 NM_004119.2(FLT3): c.2504A> T (p.Asp835Val) single nucleotide variant Pathogenic rs121909646 GRCh37 Chromosome 13, 28592641: 28592641
6 FLT3 NM_004119.2(FLT3): c.2504A> T (p.Asp835Val) single nucleotide variant Pathogenic rs121909646 GRCh38 Chromosome 13, 28018504: 28018504
7 FLT3 NM_004119.2(FLT3): c.2503G> T (p.Asp835Tyr) single nucleotide variant Pathogenic rs121913488 GRCh37 Chromosome 13, 28592642: 28592642
8 FLT3 NM_004119.2(FLT3): c.2503G> T (p.Asp835Tyr) single nucleotide variant Pathogenic rs121913488 GRCh38 Chromosome 13, 28018505: 28018505
9 FLT3 NM_004119.2(FLT3): c.1777_1779del (p.Asp593del) deletion Pathogenic rs587776834 GRCh38 Chromosome 13, 28034140: 28034142
10 FLT3 NM_004119.2(FLT3): c.1777_1779del (p.Asp593del) deletion Pathogenic rs587776834 GRCh37 Chromosome 13, 28608277: 28608279
11 PMS2 NM_000535.6(PMS2): c.1831dup (p.Ile611Asnfs) duplication Pathogenic rs63750250 GRCh37 Chromosome 7, 6026565: 6026565
12 PMS2 NM_000535.6(PMS2): c.1831dup (p.Ile611Asnfs) duplication Pathogenic rs63750250 GRCh38 Chromosome 7, 5986934: 5986934
13 NBN NM_002485.4(NBN): c.1262T> C (p.Leu421Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs104895032 GRCh37 Chromosome 8, 90967646: 90967646
14 NBN NM_002485.4(NBN): c.1262T> C (p.Leu421Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs104895032 GRCh38 Chromosome 8, 89955418: 89955418
15 NBN NM_002485.4(NBN): c.1262T> C (p.Leu421Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs104895032 NCBI36 Chromosome 8, 91036822: 91036822
16 NBN NM_002485.4(NBN): c.628G> T (p.Val210Phe) single nucleotide variant Conflicting interpretations of pathogenicity rs61754796 GRCh37 Chromosome 8, 90983475: 90983475
17 NBN NM_002485.4(NBN): c.628G> T (p.Val210Phe) single nucleotide variant Conflicting interpretations of pathogenicity rs61754796 GRCh38 Chromosome 8, 89971247: 89971247
18 NBN NM_002485.4(NBN): c.628G> T (p.Val210Phe) single nucleotide variant Conflicting interpretations of pathogenicity rs61754796 NCBI36 Chromosome 8, 91052651: 91052651
19 NBN NM_002485.4(NBN): c.1034G> T (p.Gly345Val) single nucleotide variant Uncertain significance rs587780089 GRCh37 Chromosome 8, 90971043: 90971043
20 NBN NM_002485.4(NBN): c.1034G> T (p.Gly345Val) single nucleotide variant Uncertain significance rs587780089 GRCh38 Chromosome 8, 89958815: 89958815
21 NBN NM_002485.4(NBN): c.1999T> C (p.Ser667Pro) single nucleotide variant Conflicting interpretations of pathogenicity rs587780091 GRCh37 Chromosome 8, 90958439: 90958439
22 NBN NM_002485.4(NBN): c.1999T> C (p.Ser667Pro) single nucleotide variant Conflicting interpretations of pathogenicity rs587780091 GRCh38 Chromosome 8, 89946211: 89946211
23 NBN NM_002485.4(NBN): c.2149A> T (p.Thr717Ser) single nucleotide variant Uncertain significance rs587780093 GRCh37 Chromosome 8, 90955516: 90955516
24 NBN NM_002485.4(NBN): c.2149A> T (p.Thr717Ser) single nucleotide variant Uncertain significance rs587780093 GRCh38 Chromosome 8, 89943288: 89943288
25 NBN NM_002485.4(NBN): c.425A> G (p.Asn142Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs769414 GRCh37 Chromosome 8, 90993017: 90993017
26 NBN NM_002485.4(NBN): c.425A> G (p.Asn142Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs769414 GRCh38 Chromosome 8, 89980789: 89980789
27 NBN NM_002485.4(NBN): c.456G> A (p.Met152Ile) single nucleotide variant Uncertain significance rs201816949 GRCh37 Chromosome 8, 90992986: 90992986
28 NBN NM_002485.4(NBN): c.456G> A (p.Met152Ile) single nucleotide variant Uncertain significance rs201816949 GRCh38 Chromosome 8, 89980758: 89980758
29 NBN NM_002485.4(NBN): c.505C> T (p.Arg169Cys) single nucleotide variant Uncertain significance rs182756889 GRCh37 Chromosome 8, 90990527: 90990527
30 NBN NM_002485.4(NBN): c.505C> T (p.Arg169Cys) single nucleotide variant Uncertain significance rs182756889 GRCh38 Chromosome 8, 89978299: 89978299
31 NBN NM_002485.4(NBN): c.595C> T (p.Pro199Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs587780097 GRCh37 Chromosome 8, 90983508: 90983508
32 NBN NM_002485.4(NBN): c.595C> T (p.Pro199Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs587780097 GRCh38 Chromosome 8, 89971280: 89971280
33 NBN NM_002485.4(NBN): c.119C> T (p.Ser40Leu) single nucleotide variant Uncertain significance rs587781530 GRCh37 Chromosome 8, 90995002: 90995002
34 NBN NM_002485.4(NBN): c.119C> T (p.Ser40Leu) single nucleotide variant Uncertain significance rs587781530 GRCh38 Chromosome 8, 89982774: 89982774
35 NBN NM_002485.4(NBN): c.1903A> T (p.Lys635Ter) single nucleotide variant Pathogenic/Likely pathogenic rs587782545 GRCh37 Chromosome 8, 90960063: 90960063
36 NBN NM_002485.4(NBN): c.1903A> T (p.Lys635Ter) single nucleotide variant Pathogenic/Likely pathogenic rs587782545 GRCh38 Chromosome 8, 89947835: 89947835
37 NBN NM_002485.4(NBN): c.2215C> G (p.Leu739Val) single nucleotide variant Uncertain significance rs370058152 GRCh38 Chromosome 8, 89937045: 89937045
38 NBN NM_002485.4(NBN): c.2215C> G (p.Leu739Val) single nucleotide variant Uncertain significance rs370058152 GRCh37 Chromosome 8, 90949273: 90949273
39 NBN NM_002485.4(NBN): c.2140C> T (p.Arg714Ter) single nucleotide variant Pathogenic/Likely pathogenic rs730881864 GRCh38 Chromosome 8, 89943297: 89943297
40 NBN NM_002485.4(NBN): c.2140C> T (p.Arg714Ter) single nucleotide variant Pathogenic/Likely pathogenic rs730881864 GRCh37 Chromosome 8, 90955525: 90955525
41 NBN NM_002485.4(NBN): c.775G> A (p.Glu259Lys) single nucleotide variant Uncertain significance rs201559159 GRCh38 Chromosome 8, 89970485: 89970485
42 NBN NM_002485.4(NBN): c.775G> A (p.Glu259Lys) single nucleotide variant Uncertain significance rs201559159 GRCh37 Chromosome 8, 90982713: 90982713
43 NBN NM_002485.4(NBN): c.683T> G (p.Ile228Arg) single nucleotide variant Uncertain significance rs777460725 GRCh37 Chromosome 8, 90983420: 90983420
44 NBN NM_002485.4(NBN): c.683T> G (p.Ile228Arg) single nucleotide variant Uncertain significance rs777460725 GRCh38 Chromosome 8, 89971192: 89971192
45 NBN NM_002485.4(NBN): c.1030C> T (p.Gln344Ter) single nucleotide variant Pathogenic/Likely pathogenic rs767215758 GRCh38 Chromosome 8, 89958819: 89958819
46 NBN NM_002485.4(NBN): c.1030C> T (p.Gln344Ter) single nucleotide variant Pathogenic/Likely pathogenic rs767215758 GRCh37 Chromosome 8, 90971047: 90971047
47 ETV6 NM_001987.4(ETV6): c.1153-5_1153-1delAACAG deletion Pathogenic rs786205154 GRCh37 Chromosome 12, 12038855: 12038859
48 ETV6 NM_001987.4(ETV6): c.1153-5_1153-1delAACAG deletion Pathogenic rs786205154 GRCh38 Chromosome 12, 11885921: 11885925
49 ETV6 NM_001987.4(ETV6): c.1046T> C (p.Leu349Pro) single nucleotide variant Pathogenic rs786205155 GRCh37 Chromosome 12, 12037415: 12037415
50 ETV6 NM_001987.4(ETV6): c.1046T> C (p.Leu349Pro) single nucleotide variant Pathogenic rs786205155 GRCh38 Chromosome 12, 11884481: 11884481

Copy number variations for Leukemia, Acute Lymphoblastic from CNVD:

7 (show top 50) (show all 2943)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13316 1 1 117600000 Loss Acute lymphoblastic leukemia
2 13371 17 1 22200000 Deletion TP53 Acute lymphoblastic leukemia
3 13410 1 1 2300000 Copy number Acute lymphoblastic leukemia
4 13773 1 1 35400000 Duplication Acute lymphoblastic leukemia
5 13788 1 1 40300000 Duplication Acute lymphoblastic leukemia
6 13790 1 1 46500000 Gain Acute lymphoblastic leukemia
7 13836 12 10000000 12600000 Deletion ETV6 Acute lymphoblastic leukemia
8 13906 1 100818677 103024856 Loss DPH5 Acute lymphoblastic leukemia
9 13907 1 100818677 103024856 Loss EXTL2 Acute lymphoblastic leukemia
10 13908 1 100818677 103024856 Loss OLFM3 Acute lymphoblastic leukemia
11 13909 1 100818677 103024856 Loss S1PR1 Acute lymphoblastic leukemia
12 13910 1 100818677 103024856 Loss SLC30A7 Acute lymphoblastic leukemia
13 13911 1 100818677 103024856 Loss VCAM1 Acute lymphoblastic leukemia
14 13991 1 102370195 102561809 Deletion Acute lymphoblastic leukemia
15 14292 1 106673274 107678605 Loss NTNG1 Acute lymphoblastic leukemia
16 14293 1 106673274 107678605 Loss PRMT6 Acute lymphoblastic leukemia
17 14369 1 107716342 144004701 Loss ADAM30 Acute lymphoblastic leukemia
18 14370 1 107716342 144004701 Loss ADORA3 Acute lymphoblastic leukemia
19 14371 1 107716342 144004701 Loss AFARP1 Acute lymphoblastic leukemia
20 14372 1 107716342 144004701 Loss AHCYL1 Acute lymphoblastic leukemia
21 14373 1 107716342 144004701 Loss AKNAD1 Acute lymphoblastic leukemia
22 14374 1 107716342 144004701 Loss ALX3 Acute lymphoblastic leukemia
23 14375 1 107716342 144004701 Loss AMIGO1 Acute lymphoblastic leukemia
24 14376 1 107716342 144004701 Loss AMPD1 Acute lymphoblastic leukemia
25 14377 1 107716342 144004701 Loss AMPD2 Acute lymphoblastic leukemia
26 14378 1 107716342 144004701 Loss AP4B1 Acute lymphoblastic leukemia
27 14379 1 107716342 144004701 Loss ATP1A1 Acute lymphoblastic leukemia
28 14380 1 107716342 144004701 Loss ATP5F1 Acute lymphoblastic leukemia
29 14381 1 107716342 144004701 Loss ATXN7L2 Acute lymphoblastic leukemia
30 14382 1 107716342 144004701 Loss BCAS2 Acute lymphoblastic leukemia
31 14383 1 107716342 144004701 Loss BCL2L15 Acute lymphoblastic leukemia
32 14384 1 107716342 144004701 Loss C1orf103 Acute lymphoblastic leukemia
33 14385 1 107716342 144004701 Loss C1orf152 Acute lymphoblastic leukemia
34 14386 1 107716342 144004701 Loss C1orf161 Acute lymphoblastic leukemia
35 14387 1 107716342 144004701 Loss C1orf162 Acute lymphoblastic leukemia
36 14388 1 107716342 144004701 Loss C1orf183 Acute lymphoblastic leukemia
37 15383 1 115048600 115061038 Copy number NRAS Acute lymphoblastic leukemia
38 15429 1 115400000 222100000 Gain Acute lymphoblastic leukemia
39 15832 1 119869201 120436800 Loss HMGCS2 Acute lymphoblastic leukemia
40 15833 1 119869201 120436800 Loss NBPF7 Acute lymphoblastic leukemia
41 15834 1 119869201 120436800 Loss NOTCH2 Acute lymphoblastic leukemia
42 15835 1 119869201 120436800 Loss PHGDH Acute lymphoblastic leukemia
43 15836 1 119869201 120436800 Loss REG4 Acute lymphoblastic leukemia
44 15837 1 119869201 120436800 Loss ZNF697 Acute lymphoblastic leukemia
45 15979 1 120700000 169100000 Loss CREG1 Acute lymphoblastic leukemia
46 16426 1 124300000 247249719 Deletion Acute lymphoblastic leukemia
47 16427 1 124300000 247249719 Duplication Acute lymphoblastic leukemia
48 16474 1 125000000 249250621 Copy number Acute lymphoblastic leukemia
49 16502 1 12600000 16100000 Deletion Acute lymphoblastic leukemia
50 16592 1 128000000 185104377 Copy number Acute lymphoblastic leukemia

Expression for Leukemia, Acute Lymphoblastic

Search GEO for disease gene expression data for Leukemia, Acute Lymphoblastic.

Pathways for Leukemia, Acute Lymphoblastic

Pathways related to Leukemia, Acute Lymphoblastic according to KEGG:

38
# Name Kegg Source Accession
1 Transcriptional misregulation in cancer hsa05202

Pathways related to Leukemia, Acute Lymphoblastic according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.75 MIR128-1 MIR128-2 MIR152 MIR155 MIR199B MIR203A
2 10.3 ETV6 FLT3

GO Terms for Leukemia, Acute Lymphoblastic

Cellular components related to Leukemia, Acute Lymphoblastic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.7 ACTB MIR128-1 MIR128-2 MIR130A MIR130B MIR152
2 micro-ribonucleoprotein complex GO:0035068 9.32 MIR128-1 MIR128-2 MIR130A MIR152 MIR155 MIR199B

Biological processes related to Leukemia, Acute Lymphoblastic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cholesterol homeostasis GO:0042632 9.5 MIR128-1 MIR128-2 MIR155
2 gene silencing by miRNA GO:0035195 9.36 MIR128-1 MIR128-2 MIR130A MIR130B MIR152 MIR155
3 negative regulation of lipoprotein particle clearance GO:0010985 9.26 MIR128-1 MIR128-2
4 negative regulation of lipoprotein transport GO:0140076 9.16 MIR128-1 MIR128-2
5 negative regulation of cholesterol efflux GO:0090370 9.13 MIR128-1 MIR128-2 MIR130B

Molecular functions related to Leukemia, Acute Lymphoblastic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.32 MIR128-1 MIR128-2 MIR130A MIR130B MIR152 MIR155

Sources for Leukemia, Acute Lymphoblastic

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....